Clinical Report: Assessment of Treatment Strategies for Drug-Resistant Tuberculosis
Overview
This systematic review and meta-analysis evaluates the efficacy and safety of treatment strategies for drug-resistant tuberculosis (DR-TB) across various regions. The findings highlight the ongoing challenges in managing MDR/RR-TB, including treatment success rates and adverse events associated with different regimens.
Background
Drug-resistant tuberculosis (DR-TB) is a significant public health concern, particularly multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). The global burden of MDR/RR-TB remains high, with approximately 400,000 cases reported in 2023. Effective treatment strategies are critical to improving patient outcomes and reducing mortality associated with DR-TB.
Data Highlights
No numerical data available in the provided source material.
Key Findings
The global pooled prevalence of MDR-TB is 11.6%, with isoniazid-resistant TB at 15.7% and rifampicin-resistant TB at 9.4%.
The treatment success rate for MDR/RR-TB has improved to about 68% in 2024, up from 50% in 2012.
Adverse events during treatment for DR-TB are common, with nausea, vomiting, and gastrointestinal issues frequently reported.
India, Russia, Indonesia, China, and the Philippines account for over half of the global MDR/RR-TB cases.
The WHO recommends a 6-month all-oral regimen as the preferred treatment for MDR/RR-TB patients.
Comprehensive evidence on the efficacy and safety of various DR-TB treatment strategies remains limited.
Clinical Implications
Healthcare providers should prioritize the use of the WHO-recommended 6-month all-oral regimens for treating MDR/RR-TB to enhance treatment outcomes. Awareness of potential adverse events is essential for managing patient care effectively during treatment.
Conclusion
The systematic review underscores the need for continued research and adaptation of treatment strategies for drug-resistant tuberculosis to improve patient outcomes and address the global health challenge posed by DR-TB.
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
